Hypoglycemic Agent Screen, Serum

Clinical Utility

Evaluation of suspected insulinoma characterized by hypoglycemia and increased serum insulin concentration.
Detecting drugs that stimulate insulin secretion.
Drugs detected by this procedure are:

• The first-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)
• The second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)
• The meglitinides: repaglinide (Prandin) and nateglinide (Starlix)
• The thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)

This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.

Method

Liquid chromatography-tandem mass spectrometry (LC-MS/MS)

Result Included

Chlorpropamide; Glimepiride; Glipizide; Glyburide; Nateglinide; Pioglitazone; Repaglinide; Rosiglitazone; Tolazamide; Tolbutamide

Aliases/Synonyms

Amaryl; Chlorpropamide; Dymelor; Glimepiride; Glipizide; Glucotrol; Glyburide; Meglitinides; Micronase; Prandin; Repaglinide; Sulfonylurea Hypoglycemic Serum; Sulfonylureas; Tolazamide; Tolinase; Acetohexamide; Dymelor; Orinase; Tolbutamide; Diabinese; Chlorpropamide; HYPOG; Diabinese; Actoplus Met; Actos; Avandamet; Glibenclamide; Glubrava; Glucophage; Lobeglitazone; Meglitinide; Nateglinide; Novonorm; Orinase; Pioglitazone; Piomet; Politor; PPAR; Rosiglitazone; Starlix; Surepost; Thiazolidinedione; Tolazamide; Tolbutamide; Tolinase; Troglitazone; Hypoglycemic Agents

Turnaround Time

8 days

Results

Referral Location

Out-of-Country

Last Updated

2025-11-17